Periodic Reporting for period 1 - STROBE (Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration)

Wet AMD is the leading cause of blindness in those aged 50 and over, symptoms include blurring distortion and loss of central vision which almost always affects quality of life. Lucentis (ranicizumab) is the leading licensed product for the treatment of wet AMD, however the...